Patients receiving CIMERLI® (ranibizumab-eqrn) injection with no insurance or who are insured with traditional Medicare fee-for-service (FFS) that demonstrate financial hardship and cannot afford their cost-sharing obligation may be eligible for patient assistance through the Patient Assistance Program (PAP). Patients with other government insurance, including Medicare Advantage, Medicare Part D, Fee-for-service Medicaid, Managed Medicaid, Veterans Affairs, Department of Defense, TRICARE, or any other insurance that is federally or state-funded are not eligible for Patient Assistance.
CIMERLI® can be provided at no cost to eligible underinsured* patients with financial hardship* through the Patient Assistance Program (PAP).
Patient Eligibility Criteria (must meet all to qualify)
*Functionally Underinsured means the patient does not have coverage for CIMERLI® or any other ranibizumab product (biosimilar or reference).
Proactive Alternative Funding Notifications
Coherus Solutions™ may also be able to help your patients find financial support through charitable foundations. Patient Access Specialist can research alternative coverage options for your patients.
Contact Coherus Solutions™ for detailed eligibility requirements at 1-844-483-3692 or apply online at www.coherussolutions.com
* Must meet all other eligibility requirements.
* To be considered functionally underinsured, the patient must not have coverage for CIMERLI®.
* Must meet all other eligibility requirements.
* To be considered functionally underinsured, the patient must not have coverage for CIMERLI®.
If a patient received CIMERLI™ within the past six months, they may be eligible for Retro PAP. Please contact Coherus Solutions™ at 1-844-483-3692 for additional information.
Retrospective Patient Assistance
Coherus Solutions™ may be able to assess patient eligibility for retrospective patient assistance. Please contact Coherus Solutions™ 1-844-483-3692 for additional information. Medicare patients are not eligible for retrospective patient assistance.
If eligible, the Patient Assistance Program only covers the costs of CIMERLI® and does not cover any administration or office visit costs. Restrictions may apply and not valid where prohibited by law. Coherus may revise or terminate this program without notice at any time for any reason.
Participating patients, pharmacies, physician offices and hospitals may use Coherus’ patient services web portal or send completed enrollment forms to 1-877-226-6370 to enroll patients. Under the program, if a patient incurs a co-pay obligation for the administration of CIMERLI, and meets all eligibility requirements, Coherus shall subsidize the cost of administration up-to $1000 per calendar year. The program benefit will reset every January 1st. Re-enrollment in the program is required at regular intervals. Patients may participate in the program as long as patient re-enrolls as required by Coherus BioSciences and continues to meet all of the program’s eligibility requirements during participation in the program.. After reaching the maximum program benefit, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program’s benefits cannot exceed the patient’s out-of-pocket expenses for the cost of the drug or administration fees associated with CIMERLI.